Bristol Myers Squibb

BMY gained about 1.4% to $61.64 on intraday strength followed by modest post-market gains, primarily driven by its collaboration with NVIDIA to build the life sciences field's 'most powerful' AI factory for drug discovery. Q1 2026 earnings showed EPS of $1.31 (up 9.17% year-over-year) with a net profit margin of 23.3% and ROE of 55.6%, demonstrating strong profitability. The stock stands near its 52-week high of $62.89, up approximately 15% year-to-date, trading well above both its 20-day and 60-day moving averages. However, analyst sentiment remains cautious, with Citi and Wells Fargo both maintaining Hold ratings, while the company's revenue growth remains modest (up 2.57% in Q1), suggesting market divergence on growth prospects.

Bristol-Myers Squibb declined marginally 0.28% to $60.76 today, with intraday lows reaching $60.57. Recent catalyst includes a strategic partnership with NVIDIA to build an AI factory for life sciences drug discovery, while the FDA has accepted its application for mezigdomide in multiple myeloma with a May 13, 2027 decision date. Q1 results showed solid fundamentals: operating revenue of $11.49 billion (up 2.57% YoY), EPS of $1.31 (up 9.17% YoY), and a net profit margin of 23.3%, with ROE reaching 55.57%. Year-to-date the stock has gained 13.66% and currently trades just 3.38% below its 52-week high of $62.89, above both its 20-day moving average of $58.23 and 60-day average of $57.28. Valuation metrics show a PE of 17.06 and PB of 6.18. Notable is that major brokerages including Citi and Wells Fargo maintain hold ratings, suggesting market participants remain cautious about the current valuation levels despite positive catalysts.

BMY rose 1.48% to close at 61.048, primarily driven by partnership news with NVIDIA to establish a joint AI-powered drug discovery platform for accelerating pharmaceutical development. The stock opened slightly below the prior close but recovered throughout the regular trading session, with momentum extending into post-market hours. Q1 earnings underscore underlying operational strength: EPS delivered $1.31, up 9.17% year-over-year, while operating revenue of $11.49 billion grew 2.57% from the prior year with a robust net margin of 23.3%. Technically, BMY trades 13.97% above year-start levels and within roughly 3% of its 52-week high, well above both its 20-day and 60-day moving averages. Nevertheless, analyst sentiment remains cautious with a consensus 'Hold' rating and no recent upward target revisions, reflecting some debate over the sustainability of near-term gains.

BMY declined roughly 1% today despite the company's recent announcement of partnering with Nvidia to purchase advanced AI computing systems for drug research, though market sentiment remained cautious. Pre-market trading peaked at $61.40 before closing at $60.73, while the regular session opened at $61.045 and slid to $60.16. Institutional ratings are tepid, with both Citi and Wells Fargo recently assigning Hold ratings, reflecting market concerns about the company's near-term outlook. Fundamentals remain solid: Q1 revenue reached $11.5 billion (+2.57% YoY) with a net margin of 23.3% and EPS of $1.31 (+9.17% YoY), demonstrating steady profitability. The stock trades just 4.33% below its 52-week high of $62.886, up 12.53% year-to-date, with a market cap of $122.85 billion and a moderate P/E of 16.89, suggesting the market maintains longer-term confidence despite today's weakness.

BMY displayed an intraday gap-up-and-reversal pattern today, advancing to $60.96 in pre-market before surging to $62.25 (+2.9%) during regular hours, then retreating to close at $60.74, essentially flat versus yesterday's $60.51 close. This mixed price action reflects competing narratives: on the constructive side, the FDA recently accepted the NDA for mezigdomide in multiple myeloma, with PDUFA decision set for May 13, 2027, signaling a pipeline catalyst; Q1 results showed revenue of $11.49B (+2.57% YoY), EPS of $1.31 (+9.17% YoY), net margin of 23.3%, and ROE of 55.6%. However, sell-side sentiment remains cautious—both Citi and Wells Fargo maintain Hold ratings, reflecting analyst skepticism on growth prospects. From a valuation standpoint, BMY has gained 13.62% year-to-date and now trades within 3.41% of its 52-week high of $62.89, with PE of 17.05x and market cap of $124.0B, potentially capping near-term upside.